Phillip Schwartz, PhD
Office and Contact Information
Center for Neural Stem Cell Research
1201 W La Veta
CHOC Research Institute
Orange, CA 92868
phone: (714) 509-4310
fax: (714) 509-4531
map & directions
Physician / Researcher BioTrained at UCLA's Brain Research Institute, Dr. Schwartz is a full-time stem cell biologist and holds a Senior Scientist position at the Children's Hospital of Orange County (CHOC) Research Institute. Dr. Schwartz is Managing Director of CHOC's National Human Neural Stem Cell Resource (NHNSCR), an Associate Research Biologist at the University of California, Irvine (UCI), Developmental Biology Center, and a Visiting Associate Professor in the Stem Cells and Regeneration Program of the Burnham Institute.
Dr. Schwartz' early work included studies of several models of energy failure-induced brain damage as well as preclinical and clinical studies of pharmacologic agents aimed at maintaining cerebral perfusion and/or neuroprotection. Much of this work involved translational research aimed toward improving the treatment of pediatric intensive care unit patients. For the last eight years, he has been involved in the harvest of human brains from patients that have died with neurogenetic disease and the research in his laboratory is directed towards understanding the factors influencing the behavior of human central nervous system (CNS) stem cells and multipotent CNS progenitor populations in the normal and neurogenetically diseased brain.
In collaborations on large animal models for stem cell transplantation, he has established neural stem cell lines from cats, sheep, and transgenic GFP pigs. Much of this work has been directed towards evaluating the efficacy of neural stem cell transplantation in animal models of degenerative eye diseases and of neurogenetic disease. This latter work has direct application to the clinical use of stem cells for the treatment of children with neurodevelopmental disorders, the major clinical focus of Dr. Schwartz and his clinical colleagues at CHOC. This effort also involves the use of mesenchymal stem cells harvested from human bone marrow and umbilical cord blood.
In collaborative work with scientists at UCI and the Burnham Institute, Dr. Schwartz is involved in the application of microfluidics to study migratory behavior of stem cells, the study of the effects of the extracellular matrix on stem cell proliferation and differentiation, and mechanisms of asymmetric cell division.
With scientists at UCDavis, Dr. Schwartz has been using neural stem cells harvested from patients with the Fragile X Tremor Ataxia Syndrome (FXTAS) to understand the molecular biology of this novel disease that may comprise the underlying diagnosis of a significant proportion of Parkinson's patients. Dr. Schwartz' interest in the major neurodevelopmental disorders is also reflected in his studies of stem cells taken from patients with Fragile X Syndrome, Rett Syndrome, Down's Syndrome, and various mitochondrial diseases. He is also interested in novel ways to derive human embryonic stem cell lines and has an active collaboration with a local infertility clinic for this work; a strong ethics component attaches to this effort.
A Principal Investigator of one of the NIH's 5 T15 Human Embryonic Stem Cell Culture Training Courses, Dr. Schwartz trains national and international scientists in current human embryonic and neural stem cell techniques. Dr. Schwartz regularly participates in special study sections on stem cells at the NIH. As part of the NHNSCR, Dr. Schwartz maintains clinical collaborations with several west Coast university hospitals and has active research collaborations with over 30 national and international stem cell researchers. Dr. Schwartz also regularly disseminates stem cell research information to the lay public . Dr. Schwartz' current organizational efforts have been to establish the Center for Stem Cell Transplantation at CHOC and the Stem Cell Research Center at UCI, in addition to fostering formal collaborative efforts between CHOC and UCI in stem cell research. Dr. Schwartz sits on the CHOC Ethics Committee and IACUC and is currently funded by the CHOC Foundation for Children, and by the National Institutes of Health.
Honors and Awards
- Dr Schwartz was recently awarded a “Bob and Suzanne Wright Trailblazer Award” from Autism Speaks, the world’s largest autism science and advocacy organization. The award supports, through funding, what Autism Speaks considers to be highly novel “out of t
Dr. Phil Schwartz, Director of National Human Neural Stem Cell Research
Phil Schwartz, PhD, speaks about using stem cell research to understand the disease of autism. ...
Autism Research: Dr. Schwartz, CHOC Children's
In this segment of American Health Journal, Dr. Phil Schwartz, CHOC Children's, explains how autism is currently is being diagnosed and how new new research may lead to diagnosing the disorder with a ...
|First Stem Cell Production Facility to Focus on Immune-Matching Therapies Opens at CHOC
August 05, 2014
A new stem cell production facility at Children’s Hospital of Orange County will allow researchers to produce patient-specific cells for future immune-matching therapies that could positively impact f...
|CHOC Children's Scientist Honored with Trailblazer Award From Autism Speaks
January 06, 2011
Philip H. Schwartz, Ph.D., senior scientist at the CHOC Children’s Research Institute and managing director of the facility’s National Human Neural Stem Cell Resource, was recently awarded a “Bob and ...
Xing Gong, Philip H Schwartz, Mark E Linskey, and Daniela A Bota “Neural Stem/Progenitors and Glioma Stem-like Cells Have Differential Sensitivity to Chemotherapy” Neurology (2007 Impact Factor 7.000), in press (2010).
Luo MH, Hannemann H, Kulkarni AS, Schwartz PH, O’Dowd JM, and Fortunato, EA “Human cytomegalovirus infection causes premature and abnormal differentiation of human neural progenitor cells” Journal of Virology (2007 IF 5.332), 84(7):3528-41 (2010).
Hester, ME, Song, SW, Miranda, CJ, Eagle, A, Schwartz, PH, and Kaspar, BK “Two factor reprogramming of human neural stem cells into pluripotency” PLoS ONE, 4:e7044 (2009).
Gopalakrishnan S, Van Emburgh BO, Shan J, Su Z, Fields CR, Vieweg J, Hamazaki T, Schwartz PH, Terada N, and Robertson KD “A novel DNMT3B splice variant expressed in tumor and pluripotent cells modulates genomic DNA methylation patterns and displays altered DNA binding” Molecular Cancer Research (2007 IF 4.317), 7:1622-34 (2009).
Wang RY, Cambray-Forker EJ, Ohanian K, Karlin DS, Covault KK, Schwartz PH, and Abdenur JE “Treatment reduces severity of brain imaging abnormalities in patients with MPS I and II” Molecular Genetics and Metabolism (2007 IF 2.55), 98:406-11 (2009).
Schwartz PH and Kalichman MW “Ethical Challenges to Cell-Based Interventions for the Central Nervous System: Some Recommendations for Clinical Trials and Practice” American Journal of Bioethics (2007 IF 3.934), 9:41-43 (2009).
Pistollato F, Chen HL, Schwartz PH, Basso G and Panchision DM “Hypoxia represses the differentiative effects of BMPs in high grade glioma” Stem Cells (2007 IF 7.531), 27:7-17 (2009).
Schwartz, P.H., “Training the next generation of pluripotent stem cell researchers”, Journal of Translational Medicine (2007 IF 2.94) 6:40 (2008).
Luo MH, Schwartz, PH, Fortunato, EA “Neonatal neural progenitor cells (NPCs) and their neuronal and glial derivatives are fully permissive for human cytomegalovirus infection” Journal of Virology (2007 IF 5.332), 82:9994-10007 (2008).
Jingxin Qiu, Lingbao Ai, Cheppail Ramachandran, Bing Yao, Suhasni Gopalakrishnan, C. Robert Fields, Amber L. Delmas, Lisa M. Dyer, Steven J. Melnick, Anthony T. Yachnis, Philip H. Schwartz, Howard A. Fine, Kevin D. Brown, and Keith D. Robertson “Invasion suppressor cystatin E/M (CST6): High-level cell type-specific expression in normal brain and epigenetic silencing in brain tumors” Laboratory Investigation (2007 IF 4.479), 88:910-925 (2008).
Klassen, Henry; Warfvinge, Karin; Schwartz, Philip; Kiilgaard, Jens; Shamie, Neda; Jiang, Caihui; Samuel, Melissa; Scherfig, Erik; Prather, Randall; Young, Michael “Isolation of progenitor cells from GFP-transgenic pigs and Schwartz CV 1NOV2010 - 11/1/2010 Curriculum Vitae - Philip H. Schwartz, Ph.D. - Page 25 of 43 transplantation to the retina of allorecipients” Cloning and Stem Cells (2007 IF 2.937), 10:391-402 (2008).
Mueller, FJ, Kostka, D, Ulitsky, I, Williams, R, Laurent, L, Lu, C, Rao, MS, Shamir, R, Schwartz, PH, Schmidt, NO, Loring, JF “Regulatory networks define phenotypic classes of human stem cell lines” Nature (2007 IF 28.751), 455:401-5 (2008).
Schwartz, P.H., Brick, D.J., Stover, A.E., Loring, J.F., and Mueller, F.J. “Differentiation of Neural Lineage Cells from Human Pluripotent Stem Cells” Methods (2007 IF 3.667), 45:142-158 (2008).
Schwartz, P.H. and Brick, D.J. “Stem Cell Therapies for the Lysosomal Storage Diseases – the Quintessential Neurodegenerative Diseases” Current Stem Cell Research and Therapy (2007 IF 2.94), 3:88-98 (2008).
Pistollato F, Chen HL, Schwartz PH, Basso G and Panchision DM “Oxygen tension controls the expansion of human CNS precursors and the generation of astrocytes and oligodendrocytes” Molecular and Cellular Neuroscience (2007 IF 3.994) 35:424-435 (2007).
Lee, J.P., Lee, P.J., Takahashi, H., Jeyakumar, M., Clark, D., Clarke, J., Tong, G., Wenger, D., Platt, F.M., Seyfried, T.M., Schwartz, P., Lipton, S.A., and Snyder, E.Y. “Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease” Nature Medicine (2007 IF 26.382) 13:439-447 (2007).
Klassen H, Schwartz PH, Ziaeian B, Nethercott H, Young MJ, Bragodottir R, Tullis GE, Warfvinge K and Narfstrom K “Neural precursors isolated from the developing cat brain show retinal integration following transplantation to the retina of the dystrophic cat” Veterinary Ophthalmology (2007 IF 0.820) 10:245-253 (2007).
Terskikh, A. Bryant, P.J., and Schwartz, P.H. “Mammalian Stem Cells” Pediatric Research (2007 IF 2.839), 59(4) 13R-20R (2006).
Schwartz, P.H. and Rae, S.B. “Ethical Donation of Human Embryos for Harvest of Stem Cells” Reproductive Biomedicine Online (2007 IF 2.840), 12:771-775 (2006).
Schwartz, P.H. “The Potential of Stem Cell Therapies for Neurological Diseases” Expert Reviews in Neurotherapeutics (2007 IF), 6:153-61 (2006).
Flanagan, L.A., Rebaza, L.M. Derzic, S, Schwartz, P.H., and Monuki, E.S. "Conserved Regulation of Human and Mouse Cortical Neural Stem Cells by Extracellular Matrix" Journal of Neuroscience Research (2007 IF 3.268), 83:845-856 (2006).
CM Greco, RF Berman, RM Martin, F Tassone, PH Schwartz, J Grigsby, D Hessl, EJ Becker, J Papazian, S Bacalman, MA Leehey , RJ Hagerman, PJ Hagerman “Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS)” Brain (2007 IF 8.568), 129:243-255 (2006).
Arocena, D.G., Iwahashi, C.K., Beilina, A., Ludwig, A.L., Schwartz, P.H., and Hagerman, P.J. “Induction of inclusion formation and disruption of lamin A/C structure by permutation CGG-repeat RNA in human cultured neural cells” Human Molecular Genetics (2007 IF 7.806), 14(23):3661-71 (2005). Schwartz CV 1NOV2010 - 11/1/2010 Curriculum Vitae - Philip H. Schwartz, Ph.D. - Page 26 of 43
Schwartz, P.H., Nethercott, H.E., Kirov, I.I., Ziaeian, B., Young, M.J., and Klassen, H. "Expression of Neurodevelopmental Markers by Cultured Porcine Neural Precursor Cells" Stem Cells (2007 IF 7.531), 23(9):1286-94 (2005).
Chung, B.G., Flanagan, L.A., Rhee, S.W., Schwartz, P.H., Lee, A.P., Monuki, E.S., Jeon, N.L. "Human Neural Stem Cell Growth and Differentiation in a Gradient-Generating Microfluidic Device" Lab on a Chip (2007 IF 5.068), 5(4):401-6 (2005).
Schwartz, P.H., Tassone, F., Greco, C.M., Nethercott, H.E., Ziaeian, B., Hagerman, R.J., and Hagerman, P.J. "Neural Progenitor Cells from an Adult Patient with Fragile X Syndrome" BMC Medical Genetics (2007 IF 2.419), 6:2-24 (2005).
Klassen, H., Ziaeian, B., Kirov, I.I., Young, M.J., and Schwartz, P.H. "Isolation of Retinal Progenitor Cells from Postmortem Human Tissue with Comparison to Autologous Brain Progenitors" J. Neurosci. Res. (2007 IF 3.268), 77:334-343 (2004), with cover.
Beilina, S., Tassone, F., Schwartz, P.H., Sahota, P., and Hagerman, P.J. "Redistribution of transcription start sites within the FMR1 promoter region with expansion of the downstream CGG-repeat element" Hum. Mol. Genet. (2007 IF 7.806) 13:543-549 (2004).
Fuja, T.J., Schwartz, P.H., Darcy, D. and Bryant, P.J. “Asymmetric Localization of LGN but not AGS3, Two Homologs of Drosophila Pins, in Dividing Human Neural Progenitor Cells.” J. Neurosci. Res. (2007 IF 3.268) 75:782-793 (2004), with cover.
Schwartz, P.H., Bryant, P.J., Fuja, T.J., Su, H., O'Dowd, D.K., and Klassen, H.K. "Isolation and Characterization of Neural Progenitor Cells form Post-Mortem Human Cortex." J. Neurosci. Res. (2007 IF 3.268)74:838-851 (2003), with cover.
Palmer, T.D., Schwartz, P.H., Taupain, P., Kaspar, B., Stein, S.A., and Gage, F.H. “Stem Cells grown from Postmortem Human Brain” Nature (2007 IF 28.751)411:42-43 (2001).
Truong, D.D., Kanthasamy, A., Nguyen, B., Matsumoto, R., and Schwartz, P. “Animal Models of Posthypoxic Myoclonus: I. Development and Validation” Mov. Disord. (2007 IF 3.207)15(Suppl. 1):26-30 (2000).
Truong, D.D., Matsumoto, R.R., Schwartz, P.H., Hussong, M.J., and Wasterlain, C.G. “Novel Rat Cardiac Arrest Model of Posthypoxic Myoclonus” Mov Disord (2007 IF 3.207)9(2):201-6 (1994).
Wasterlain, C.G., Adams, L.M., Schwartz, P.H., Hattori, H., Sofia, R.D., and Wichmann, J.K. “Posthypoxic Treatment with Felbamate is Neuroprotective in a Rat Model of Hypoxia-Ischemia” Neurology (2007 IF 6.014) 43(11):2303-10 (1993).
Schwartz, P.H. and Wasterlain, C.G. “Determination of Serum and Brain Concentrations of Neuroprotective and Non-Neuroprotective Doses of MK-801” J Neurol Sci (2007 IF 2.315) 115(1):26-31 (1993).
Reyes, G., Schwartz, P.H., Newth, C.J., and Eldadah, M.K. “The Pharmacokinetics of Isoproterenol in Critically Ill Pediatric Patients” J Clin Pharmacol (2007 IF 2.993) 33(1):29-34 (1993).
Fisher, D.G., Schwartz, P.H., and Davis, A.L. “Pharmacokinetics of Exogenous Epinephrine in Critically Ill Children” Crit Care Med (2007 IF 6.283) 21(1):111-7 Schwartz CV 1NOV2010 - 11/1/2010 Curriculum Vitae - Philip H. Schwartz, Ph.D. - Page 27 of 43 (1993).
Schwartz, P.H., Massarweh, W.F., Vinters, H.V., Dwyer, B.E., Fujikawa, D.G., and Wasterlain C.G. "A Rat Model of Severe Neonatal Hypoxic-Ischemic Brain Injury" Stroke (2007 IF 6.296) 23:539-546 (1992).
Wasterlain, C.G., Hattori, H., Adams, L.M., and Schwartz, P.H. "Felbamate reduces Hypoxic-Ischemic Brain Damage In Vivo" Eur. J. Pharmacol. (2007 IF 2.376) 212:275-278 (1992).
Schwartz, P.H. and Wasterlain, C.G. "Cardiac Arrest alters the Pharmacokinetics of MK-801 in the Rat" Res. Comm. Chem. Pathol. Pharmacol. (2007 IF), 73:181-195 (1991).
Eldadah, M.K., Schwartz, P.H., Harrison, R., Newth, C.J. "The Pharmacokinetics of Dopamine in Infants and Children" Crit. Care Med. (2007 IF 6.283), 19:1008-1011 (1991).
Sivan, Y., Schwartz, P.H., Schonfeld, T., Cohen, I.J., and Newth, C.J. "Outcome of Oncology Patients in the Pediatric Intensive Care Unit" Intensive Care Med. (2007 IF 4.623), 17:11-15 (1991).
Schwartz, P.H., Eldadah, M.K., and Newth, C.J.L. "The Pharmacokinetics of Dobutamine in Pediatric Intensive Care Unit Patients" Drug Metab. Dispos. (2007 IF 3.907), 19:614-619 (1991).
Hattori, H., Morin, A.M., Schwartz, P.H., Fujikawa, D.G., and Wasterlain, C.G. "Post-Hypoxic Treatment with MK-801 reduces Hypoxic-Ischemic Damage in the Neonatal Rat" Neurology (2007 IF 6.014) 39:713-718 (1989).
Sinniah, D., Schwartz, P.H., Mitchell, R.A., and Arcinue, E.L. "Investigation of an Animal Model of a Reye-like Syndrome Caused by Margosa Oil" Ped. Res. (2007 IF 2.839) 19:1346-1355 (1985).